Propofol shortage resolved; Genzyme gets familiar face as new CEO;

> Hospira ($HSP) and APP Pharma ($APPX) report that the propofol drug shortage has been resolved. FDA listing

> Sanofi ($SNY) has announced the appointment of David Meeker as CEO of the Genzyme unit, effective November 1; Meeker is currently Genzyme's COO. Sanofi CEO Christopher Viehbacher (photo) will remain Genzyme chairman. Release

> Regulatory pressure and a more detailed understanding of costs will push drugmakers to change their minds about outsourcing and take back control of APIs and components. Article (sub. req.)

> The New Jersey Department of Labor and Workforce Development has made available $3.6 million in federal funding for retraining and re-employment opportunities for laid-off pharma workers. Story

> Contract manufacturer Patheon ($PTI) has won two contracts, worth $18 million, to make experimental Type 2 diabetes drugs for Boehringer Ingelheim. News

> Lonza (LONN:VX) has formed Lonza Microbial Control after completing the acquisition of Arch Chemicals. Story

> In a Pharma IQ survey, 57% of respondents report that migrating single-use systems from development into a commercial state is a main goal. Item

> The future for aseptic operations is isolated robotics. Column

> Almac says it will expand its pharma development services with a new facility in Craigavon, Ireland. Release

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.